Shoeshine
|
Friday 14th November 2003 |
Text too small? |
The issues are old ones. First, the company didn't live up to the 2001 information memorandum ebitda (earnings before interest, tax, depreciation and amortisation) forecast of $18.3 million for the August 2002 year.
That's disappointing for everyone but in the context of a rocketing exchange rate, low beef prices for Tru-Test's customers and the Australian drought, it's scarcely surprising.
The Neuronz purchase has also aggravated some shareholders but, like the company's financial performance, that was known before last year's annual meeting, at which, apparently, no questions were asked.
The theory getting most traction is that someone is trying to unsettle shareholders and turn up the gas on Tru-Test's board and management to smooth the path of a takeover.
The natural candidate for the bidder is Skellmax Industries, whose largest shareholder, Axa Asia Pacific, has 5.67%.
It's a small country. Axa is also one of Tru-Test's shareholders.
No comments yet
GTK - FY26 Investor Briefing Details
ERD - HY27 Financial Results Briefing Details - Amended
SEK - Forsyth Barr Initiates Coverage on Seeka
PHL - HY27 results: first dividend and upgraded guidance
PYS - PaySauce to announce F27 interim results on 26 Nov 2026
ERD - HY27 Financial Results Briefing Details
RAD - Radius Health Profit up 27%; Increased Dividend
CHI - Channel presentation to the UBS Australasia Conference 2026
CCC - Cooks Coffee Company Trading Update
November 10th Morning Report